KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

IonQ (IONQ) Other Operating Expenses (2020 - 2025)

IonQ has reported Other Operating Expenses over the past 6 years, most recently at $93.5 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $93.5 million for Q4 2025, up 500.01% from a year ago — trailing twelve months through Dec 2025 was $183.7 million (up 236.24% YoY), and the annual figure for FY2025 was $183.7 million, up 236.24%.
  • Other Operating Expenses for Q4 2025 was $93.5 million at IonQ, up from $50.6 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for IONQ hit a ceiling of $93.5 million in Q4 2025 and a floor of $553000.0 in Q1 2021.
  • Median Other Operating Expenses over the past 5 years was $7.1 million (2023), compared with a mean of $14.3 million.
  • Biggest five-year swings in Other Operating Expenses: fell 4.43% in 2021 and later surged 500.01% in 2025.
  • IonQ's Other Operating Expenses stood at $1.5 million in 2021, then skyrocketed by 159.71% to $3.8 million in 2022, then surged by 195.68% to $11.2 million in 2023, then skyrocketed by 39.7% to $15.6 million in 2024, then surged by 500.01% to $93.5 million in 2025.
  • The last three reported values for Other Operating Expenses were $93.5 million (Q4 2025), $50.6 million (Q3 2025), and $24.6 million (Q2 2025) per Business Quant data.